McDonald, D., Ackermann, G., Khailova, L., Baird, C., Heyland, D., Kozar, R.. Extreme dysbiosis of the microbiome in critical illness. mSphere. 2016; 1 (4)

Schneider, S.M.. [Microbiota and enteral nutrition]. Gastroenterol. Clin. Biol.. 2010; 34 (Suppl 1): S57-S61

Xie, C., Li, J., Wang, K., Li, Q., Chen, D.. Probiotics for the prevention of antibiotic-associated diarrhoea in older patients: a systematic review. Travel Med. Infect. Dis.. 2015; 13 (2): 128-134

Maraolo, A.E.. Reassessing the death risk related to probiotics in critically ill patients. Crit. Care. 2016; 20 (1): 388

Manzanares, W., Lemieux, M., Langlois, P.L., Wischmeyer, P.E.. Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis. Crit. Care. 2016; 19: 262

Roy, U., Jessani, L.G., Rudramurthy, S.M., Gopalakrishnan, R., Dutta, S., Chakravarty, C.. Seven cases of Saccharomyces fungaemia related to use of probiotics. Mycoses. 2017

van der Aa Kühle, A., Jespersen, L.. The taxonomic position of Saccharomyces boulardii as evaluated by sequence analysis of the D1/D2 domain of 26S rDNA, the ITS1-5.8S rDNA-ITS2 region and the mitochondrial cytochrome-c oxidase II gene. Syst. Appl. Microbiol.. 2003; 26 (4): 564-571

Tiago, F.C., Martins, F.S., Souza, E.L., Pimenta, P.F., Araujo, H.R., Castro, I.M.. Adhesion to the yeast cell surface as a mechanism for trapping pathogenic bacteria by Saccharomyces probiotics. J. Med. Microbiol.. 2012; 61 (Pt 9): 1194-1207

Castagliuolo, I., Riegler, M.F., Valenick, L., LaMont, J.T., Pothoulakis, C.. Saccharomyces boulardii protease inhibits the effects of Clostridium difficile toxins A and B in human colonic mucosa. Infect. Immun.. 1999; 67 (1): 302-307

McFarland, L.V.. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am. J. Gastroenterol.. 2006; 101 (4): 812-822